Deconvoluting Kinase Inhibitor Induced Cardiotoxicity

Many drugs designed to inhibit kinases have their clinical utility limited by cardiotoxicity-related label warnings or prescribing restrictions. While this liability is widely recognized, designing safer kinase inhibitors (KI) requires knowledge of the causative kinase(s). Efforts to unravel the kin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamore, Sarah D., Ahlberg, Ernst, Boyer, Scott, Lamb, Michelle L., Hortigon-Vinagre, Maria P., Rodriguez, Victor, Smith, Godfrey L., Sagemark, Johanna, Carlsson, Lars, Bates, Stephanie M., Choy, Allison L., Stålring, Jonna, Scott, Clay W., Peters, Matthew F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Kinase Inhibitors and Cardiotoxicity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837613/
https://www.ncbi.nlm.nih.gov/pubmed/28453775
http://dx.doi.org/10.1093/toxsci/kfx082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837613/
https://www.ncbi.nlm.nih.gov/pubmed/28453775
http://dx.doi.org/10.1093/toxsci/kfx082

Ejemplares similares